77
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Toll-like receptor 3 gene expression in Egyptian patients with glomerulonephritis and hepatitis C virus infection

&
Pages 456-461 | Received 17 Dec 2010, Accepted 18 Apr 2011, Published online: 30 May 2011
 

Abstract

Background. Hepatitis C virus (HCV) infection is associated with both chronic liver disorders and several extrahepatic manifestations including renal disease. Toll-like receptor 3 (TLR3), a component of the innate immune system, is a pathogen recognition receptor that recognizes viral double-stranded RNA. Objective. This work investigated TLR3 expression in peripheral blood mononuclear cells from HCV-positive patients with glomerulonephritis. Methods. One hundred and thirty patients with glomerulonephritis were initially enrolled in the study. After exclusion of 52 patients with secondary glomerulonephritis, 78 patients were screened for HCV infection. TLR3 expression in peripheral blood mononuclear cells was studied in 46 patients with HCV-positive glomerulonephritis and 32 patients with HCV-negative glomerulonephritis using a real-time PCR comparative quantitation approach and results were compared to a control group of 20 healthy subjects. Results. TLR3 expression was significantly higher in patients with HCV-positive glomerulonephritis than in HCV negative patients and controls (p < 0.0001). TLR3 expression correlated positively with HCV viral load, interleukin-1β, serum creatinine and inversely with creatinine clearance in patients with HCV-positive glomerulonephritis. Conclusion. This work shows that TLR3 expression is upregulated in HCV-positive patients with glomerulonephritis. Overexpression is associated with reduced renal function and increased interleukin 1β level.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.